Abstract: The present disclosure provides a method of processing data based on QUIC protocol stack, the method including: obtaining a connection identifier of a data packet; determining a server program used for processing the data packet, wherein the server program comprises a plurality of worker threads, wherein QUIC protocol stacks run in the plurality of worker threads; determining a corresponding worker thread from the multiple worker threads based on the connection identifier; and distributing the data packet to the corresponding worker thread to make the QUIC protocol stack on the corresponding worker thread process the data packet. The disclosure further provides a system, a computing device and a computer-readable storage medium of processing data based on QUIC protocol stack.

Abstract: Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: An optimal detection voltage obtaining method, a reading control method and an apparatus are provided.

Abstract: An optimal detection voltage obtaining method, a reading control method and an apparatus are provided.

Abstract: Compounds of the present application or pharmaceutically acceptable salts thereof are provided and methods involving compounds of the present application as effective inhibitors of NEK are also provided.

Abstract: In one aspect, the present disclosure provides trioxacarcin analogs of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein as well as dimers of the compounds described herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.

Abstract: Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

Abstract: In one aspect, the present invention provides novel derivatives of trioxacarin analogs of the formula (I) wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.

Abstract: Disclosed herein are protein-targeting chimeric molecules (PROTACs) that recruit a specific ubiquitin ligase, such as LRL4DCAF15, to a chosen target protein, causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: Compounds of the present application or pharmaceutically acceptable salts thereof are provided and methods involving compounds of the present application as effective inhibitors of NEK are also provided.

Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: In one aspect, the present invention provides novel derivatives of trioxacarin analogs of the formula (I) wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.

Abstract: The present invention provides methods for screening for one or more chemical agents that modulate the enzymatic activity of an L-2-hydroxy acid oxidase. The methods comprise the steps of (a) contacting an L-2-hydroxy acid oxidase, in a solution in vitro, with one or more chemical agents in the presence of a substrate that is capable of being oxidized by the L-2-hydroxy acid oxidase; (b) measuring the enzymatic activity of the L-2-hydroxy acid oxidase in the presence of the chemical agent to identify one or more candidate chemical agents that modulate L-2-hydroxy acid oxidase activity in vitro; and (c) administering the one or more identified candidate chemical agents to a test animal and measuring one or more physiological parameters.

Abstract: Transgenic mice having human CETP genes are useful models for the action of niacin in humans. Such animals exhibit an increase in HDL-C and the HDL-C/non-HDL-C ratio and a decrease in non-HDL-C when they are treated with niacin. The changes in HDL-C and non-HDL-C appear to be dose-dependent.

Abstract: An adjustable armrest assembly for a chair includes an arm support having an end formed with a connecting body, a slide slidably mounted and detachably locked on the connecting body of the arm support, and an armrest secured to the slide. Thus, the position of the armrest is adjustable to fit users of different statures, so that the user's hands are placed on the armrest in a comfortable manner. In addition, the position of the armrest is adjusted easily and conveniently, thereby facilitating the user adjusting the position of the armrest.

Abstract: The instant invention provides a drug combination comprised of an HMG-CoA reductase inhibitor in combination with an ACAT inhibitor, which is useful for treating or preventing Alzheimer's disease.